ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $113 | $83 | $50 | $41 |
| % Growth | 36.4% | 66.7% | 21.1% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $0 |
| Gross Profit | $111 | $82 | $49 | $41 |
| % Margin | 98.1% | 98.9% | 98.7% | 99.6% |
| R&D Expenses | $48 | $50 | $52 | $58 |
| G&A Expenses | $0 | $36 | $0 | $24 |
| SG&A Expenses | $38 | $36 | $40 | $42 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $18 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $85 | $86 | $92 | $101 |
| Operating Income | $26 | -$4 | -$42 | -$60 |
| % Margin | 22.9% | -5% | -85% | -144.7% |
| Other Income/Exp. Net | $4 | $1 | $1 | $2 |
| Pre-Tax Income | $30 | -$3 | -$41 | -$58 |
| Tax Expense | -$1 | $1 | -$0 | $1 |
| Net Income | $31 | -$4 | -$41 | -$59 |
| % Margin | 27.1% | -5.1% | -81.3% | -143.3% |
| EPS | 0.1 | -0.016 | -0.16 | -0.23 |
| % Growth | 721.1% | 89.9% | 30.4% | – |
| EPS Diluted | 0.1 | -0.016 | -0.16 | -0.23 |
| Weighted Avg Shares Out | 273 | 263 | 259 | 253 |
| Weighted Avg Shares Out Dil | 288 | 263 | 259 | 254 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $2 | $2 | $2 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $2 | $3 |
| EBITDA | $31 | -$2 | -$38 | -$54 |
| % Margin | 27.4% | -2.2% | -76.1% | -131.4% |